Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer's Disease and Correlates with Cognitive Impairment

Oeckl, Patrick; Halbgebauer, Steffen; Anderl-Straub, Sarah; Steinacker, Petra; Huss, Andre M.; Neugebauer, Hermann; Arnim, Christine A. F. von; Diehl-Schmid, Janine; Grimmer, Timo; Kornhuber, Johannes; Lewczuk, Piotr; Danek, Adrian; Ludolph, Albert C. und Otto, Markus (2019): Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer's Disease and Correlates with Cognitive Impairment. In: Journal of Alzheimers Disease, Bd. 67, Nr. 2: S. 481-488

Abstract

Reliable blood biomarkers for Alzheimer's disease (AD) are missing. We measured astroglial GFAP in patients with AD (n = 28), frontotemporal dementia (bvFTD, n = 35), Parkinson's disease (n = 11), Lewy body dementias (n = 19), and controls (n = 34). Serum GFAP was increased in AD (p < 0.001) and DLB/PDD (p < 0.01), and cerebrospinal fluid GFAP was increased in all neurodegenerative diseases (p < 0.001). Serum GFAP correlated with the Mini-Mental State Examination score (r = -0.42, p < 0.001) and might be a follow-up marker in clinical trials. Sensitivity and specificity of serum GFAP for AD versus bvFTD was 89% and 79% and might be the first blood biomarker in the differential diagnosis of AD and bvFTD.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 1387-2877
• Sprache: Englisch